BEKE vs SBAC

BEKE's deterministic health scores signal significant distress: the Piotroski F-Score of 3/9 indicates weak financial health, with deteriorating profitability and negative earnings growth. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given the company's declining earnings and high payout ratio. While the Graham Number ($9.15) suggests undervaluation, the current price of $16.90 trades at a substantial premium, reflecting overoptimistic growth expectations. Analysts recommend 'buy' with a target of $20.68, but this is inconsistent with the company's weak fundamentals and negative earnings trajectory. The stock has underperformed over multiple time horizons, including a 5-year decline of 73.3%.

SBAC exhibits strong operational health with a Piotroski F-Score of 8/9, indicating robust financial fundamentals despite a lack of Altman Z-Score data. The stock is currently trading at a significant discount to its growth-based intrinsic value of $289.1, providing a substantial margin of safety. While liquidity ratios are alarmingly low (Current Ratio 0.29), this is common in the REIT sector; however, the combination of high operating margins (52.44%) and a sustainable dividend payout supports a positive outlook. The bullish assessment is further reinforced by a strong analyst consensus and recent short-term price momentum.